1. International Journal of Cardiology
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non- valvular atrial fibrillation 
Hiroaki Shimokawa, Takeshi Yamashita, Shinichiro Uchiyama, Takanari Kitazono, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Ichiro Sakuma, Keijiro Saku, Yasuo Okumura, Yuichiro Nakamura, Hideo Morimoto, Naoki Matsumoto, Akihito Tsuchida, Junya Ako, Nobuyoshi Sugishita, Shogo Shimizu, Hirotsugu Atarashi, Hiroshi Inoue 
International Journal of Cardiology 
Volume 258, Pages (May 2018)
DOI: /j.ijcard
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1
Kaplan–Meier analysis for primary endpoints and all-cause deaths (efficacy and safety populations).
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 2
The primary efficacy endpoint (A) (stroke or systemic embolism) and primary safety endpoint (B) (major bleeding) according to CHADS2 and CHA2DS2-VASc scores.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2018 The Authors Terms and Conditions